Weight Loss

On Wednesday, Novo Nordisk A/S (NYSE:NVO) submitted its supplemental marketing application to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg for chronic weight management. NVO is among today's top performers. See the trading setup here The new,...

Novo Nordisk A/S (NYSE:NVO) on Tuesday released headline results from a phase 2 trial with amycretin for type 2 diabetes. The update marks the first evaluation of amycretin in people with type 2 diabetes. Novo Nordisk is planning to initiate a phase 3 development program with amycretin for adults...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Monday released topline results from its randomized controlled clinical study (VP-VLY-686-2601) evaluating tradipitant to prevent nausea and vomiting induced by Wegovy. VNDA is surging to new heights today. See the full breakdown here The trial studied...

Novo Nordisk A/S (NYSE:NVO) announced on Monday that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are now available at a limited-time price of $199 per month to new self-pay patients between now and March 31, 2026. • NVO is gathering positive momentum. Check the...

Eli Lilly & Co. (NYSE:LLY) is reportedly dropping CVS Health Inc.'s (NYSE:CVS) drug benefit plan for its employees. CVS is trading near recent highs. Review the technical setup here. What Went Down Earlier in May this year, Novo Nordisk A/S (NYSE:NVO) announced that CVS Health's CVS...

On Thursday, Eli Lilly and Co. (NYSE:LLY) released data from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 obese adults with at least one obesity-related health issue and without type 2 diabetes. At 48...

President Donald Trump on Thursday announced agreements with Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) to significantly reduce prices for their GLP-1-based obesity and diabetes drugs. The deals will also expand Medicare and Medicaid coverage for these high-demand treatments...

At the ObesityWeek, Novo Nordisk A/S (NYSE:NVO) presented new findings from the STEP UP phase 3b trial. The Novo Nordisk STEP UP phase 3b trial investigated the efficacy and safety of a higher, 7.2 mg dose of semaglutide compared to the 2.4 mg dose and a placebo for weight management in adults with...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported third-quarter 2025 sales of roughly $11.75 billion (74.98 billion Danish kroner), slightly below the consensus of $11.88 billion. Sales increased by 5% in Danish kroner and 11% at constant currency. GLP-1 diabetes sales increased by 11% to 36.74...

Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid. And in the middle of it all — a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches....

On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO). Metsera said the proposal constitutes a “Superior Company Proposal” as defined in Metsera’s existing Merger Agreement with Pfizer Inc (NYSE:PFE). In...

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that...

Eli Lilly and Co. (NASDAQ:LLY) plans to invest over $1 billion in India to strengthen its manufacturing network, according to Reuters. The move aims to tap into the country's skilled workforce and support Lilly's global expansion. The collaborations are designed to increase the availability of key...

Skye Bioscience Inc. (NASDAQ:SKYE) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab. The nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo (-1.52% vs. -0.26 for placebo...